Cargando…
Little genomic support for Cyclophilin A-matrix metalloproteinase-9 pathway as a therapeutic target for cognitive impairment in APOE4 carriers
Therapeutic targets for halting the progression of Alzheimer’s disease pathology are lacking. Recent evidence suggests that APOE4, but not APOE3, activates the Cyclophilin-A matrix metalloproteinase-9 (CypA-MMP9) pathway, leading to an accelerated breakdown of the blood–brain barrier (BBB) and there...
Autores principales: | Anderson, Emma L., Williams, Dylan M., Walker, Venexia M., Davies, Neil M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776806/ https://www.ncbi.nlm.nih.gov/pubmed/35058547 http://dx.doi.org/10.1038/s41598-022-05225-8 |
Ejemplares similares
-
Expression and prognostic relevance of Cyclophilin A and matrix metalloproteinase 9 in esophageal squamous cell carcinoma
por: Li, Yi, et al.
Publicado: (2013) -
APOE4 impairs blood-brain barrier via cyclophilin A
Publicado: (2012) -
Serum Matrix Metalloproteinase‐9 and Cognitive Impairment After Acute Ischemic Stroke
por: Zhong, Chongke, et al.
Publicado: (2018) -
Variants of the Matrix Metalloproteinase-2 but not the Matrix Metalloproteinase-9 genes significantly influence functional outcome after stroke
por: Manso, Helena, et al.
Publicado: (2010) -
Important role of matrix metalloproteinase 9 in epileptogenesis
por: Wilczynski, Grzegorz M., et al.
Publicado: (2008)